# A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

> **NCT06059846** · PHASE3 · COMPLETED · sponsor: **Spero Therapeutics** · enrollment: 1690 (actual)

## Conditions studied

- Urinary Tract Infection
- Acute Pyelonephritis

## Interventions

- **DRUG:** TBP-PI-HBr
- **DRUG:** Imipenem-cilastatin
- **DRUG:** Dummy Infusion
- **DRUG:** Dummy Tablets

## Key facts

- **NCT ID:** NCT06059846
- **Lead sponsor:** Spero Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-21
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-02-06
- **Target enrollment:** 1690 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06059846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06059846, "A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06059846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*